340B, Eli Lilly

The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...
Johnson & Johnson and Eli Lilly both sued the federal government this month over the future of their respective 340B drug rebate plans.
The AHA Nov. 15 filed friend-of-the-court briefs in the U.S. Court of Appeals for the 5th Circuit in support of an earlier denial by the U.S. District Court for the Southern District of Mississippi of ...
Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...
Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...
The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
California is poised to pass a ballot measure aimed at imposing 340B spending restrictions for certain healthcare entities participating in the ...